| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/06/2005 | WO2005000246A2 Methods and compositions for treating rheumatoid arthritis |
| 01/06/2005 | WO2005000245A2 Compositions and methods for increasing telomerase activity |
| 01/06/2005 | WO2005000244A2 Methods and compositions for treating rheumatoid arthritis |
| 01/06/2005 | WO2005000243A2 The polymorphic form a of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butryric acid |
| 01/06/2005 | WO2005000240A2 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 01/06/2005 | WO2005000239A2 Lyase treatment for p. carinii |
| 01/06/2005 | WO2005000238A2 Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis |
| 01/06/2005 | WO2005000236A2 Transdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| 01/06/2005 | WO2005000233A2 Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders |
| 01/06/2005 | WO2005000232A2 Six membered amino-amide derivatives as angiogenesis inhibitors |
| 01/06/2005 | WO2005000231A2 Il-8 receptor antagonists |
| 01/06/2005 | WO2005000230A2 Methods of treating hyperproliferative cell disorders |
| 01/06/2005 | WO2005000229A2 Compositions and methods for modulating s-nitrosoglutathione reductase |
| 01/06/2005 | WO2005000227A2 Methods of treating tnf-mediated disorders |
| 01/06/2005 | WO2005000224A2 Novel dermatological composition |
| 01/06/2005 | WO2005000219A2 Composition for blocking hiv binding to dendritic cells and methods of use thereof |
| 01/06/2005 | WO2005000217A2 Combination therapy for the treatment of dyslipidemia |
| 01/06/2005 | WO2005000216A2 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| 01/06/2005 | WO2005000214A2 Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics |
| 01/06/2005 | WO2005000213A2 Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors |
| 01/06/2005 | WO2005000212A2 Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors |
| 01/06/2005 | WO2005000211A2 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes |
| 01/06/2005 | WO2005000210A2 Synthesis of high molecular weight iron-saccharidic complexes |
| 01/06/2005 | WO2005000208A2 Combination therapy for the treatment of neoplasms |
| 01/06/2005 | WO2005000205A2 Methods and compositions for modulating serum cortisol levels |
| 01/06/2005 | WO2005000204A2 Pancreatic cancer treatment |
| 01/06/2005 | WO2005000203A2 Methods for treating cognitive impairment and improving cognition |
| 01/06/2005 | WO2005000196A2 Inhibition of egr-1 expression by rpar-ϝ agonista and related compositions and methods |
| 01/06/2005 | WO2005000174A1 Transdermal dietary parthenolide and/or feverfew extract |
| 01/06/2005 | WO2005000109A2 Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids |
| 01/06/2005 | WO2005000041A1 Combinations of vasoprotective agents and formulations containing them |
| 01/06/2005 | WO2005000040A1 Infant formula |
| 01/06/2005 | WO2005000032A1 Method for treatment of sores and lesions of the skin |
| 01/06/2005 | WO2004106486A3 Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
| 01/06/2005 | WO2004103348A3 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| 01/06/2005 | WO2004096862A3 Improved extration and purification method for cereal beta (1-3) beta (1-4) glucan |
| 01/06/2005 | WO2004096138A3 [18f]-furanosylpurine derivatives and uses thereof |
| 01/06/2005 | WO2004095942A3 Caffeinated tablet |
| 01/06/2005 | WO2004093800A3 Thyronamine derivatives and analogs and methods of use thereof |
| 01/06/2005 | WO2004092736A3 Derivatives of azithromycin |
| 01/06/2005 | WO2004089417A9 Drug-enclosing multilayer structure particulate and process for producing the same |
| 01/06/2005 | WO2004089396A3 Anti-fungal peptidomimetics |
| 01/06/2005 | WO2004087646A3 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
| 01/06/2005 | WO2004087141B1 Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases |
| 01/06/2005 | WO2004078216A3 Use of a tricyclic antidepressant drug for promoting endocytosis |
| 01/06/2005 | WO2004076445A3 Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| 01/06/2005 | WO2004071449A3 Lactams as modulators of chemokine receptor activity |
| 01/06/2005 | WO2004071388A3 Medicinal compounds |
| 01/06/2005 | WO2004071385A3 Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin ii antagonist for stroke prevention |
| 01/06/2005 | WO2004071380A3 Drugs containing substituted 2-aryl-aminoacetic acid compounds |
| 01/06/2005 | WO2004069796A3 Process for producing levetiracetam |
| 01/06/2005 | WO2004069202A3 Antiglucocorticoids for the treatment of postpartum psychosis |
| 01/06/2005 | WO2004066936A3 Method and assembly for liquid nitrogen therapy |
| 01/06/2005 | WO2004062657A8 Acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein |
| 01/06/2005 | WO2004037750A3 Short-acting sedative hypnotic agents for anesthesia and sedation |
| 01/06/2005 | WO2004022066A3 Method and means for the treatment of vascular and cardiac diseases |
| 01/06/2005 | WO2004019959A3 Dna repair enzymes |
| 01/06/2005 | WO2003103643A8 Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor |
| 01/06/2005 | WO2003042177A8 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 01/06/2005 | WO2003041654A3 Anti-estrogen and immune modulator combinations for treating breast cancer |
| 01/06/2005 | WO2003032912A9 Treatment of cns disorders using cns target modulators |
| 01/06/2005 | WO2002055700A8 Human genes and gene expression products isolated from human prostate |
| 01/06/2005 | WO1999044608A8 New use |
| 01/06/2005 | US20050005329 Isolated nucleotide sequence encoding polypeptide derived from algae Isochrysis galbana; expression of vector results in production of polyunsaturated fatty acid; use in pharmaceutical compositions, animal feeds and cosmetics |
| 01/06/2005 | US20050005328 Nucleotide sequence encoding a polypeptide derived from fungus Thraustochytrium aureum; expression of vector results in production of polyunsaturated fatty acid (omega 6-docosapentaenoic acid and docosahexaenoic acid); use in pharmaceutical compositions, animal feeds and cosmetics |
| 01/06/2005 | US20050004663 Heparin barrier coating for controlled drug release |
| 01/06/2005 | US20050004517 Embolization protection system for vascular procedures |
| 01/06/2005 | US20050004510 Noninvasive vascular therapy |
| 01/06/2005 | US20050004382 Meiosis regulating compounds |
| 01/06/2005 | US20050004381 Therapy for headaches; analgesics; nausea; anxiolytic agents; anticonvulsants; central nervous system disorders |
| 01/06/2005 | US20050004360 Compounds and methods for modulation of estrogen receptors |
| 01/06/2005 | US20050004358 Formed by treatment with isopropyl alcohol and elimination of lipophilic substances; fermentation, centrifugation, and ultrafiltration |
| 01/06/2005 | US20050004356 Linker nucleoside, its preparation and use |
| 01/06/2005 | US20050004352 Single-chain multiple antigen-binding molecule, its preparation and use |
| 01/06/2005 | US20050004348 Sodium transport protein for use as tool in identifying modulator for treatment of hyperphosphatemia or hypophosphatemia |
| 01/06/2005 | US20050004274 Ester with one or more triblock copolymers having rigid and elastic sections; mineral oil free; vehicles for topical materials |
| 01/06/2005 | US20050004235 Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease |
| 01/06/2005 | US20050004234 Formulations for anaesthetic use |
| 01/06/2005 | US20050004232 Acyl sulfonamides as inhibitors of HIV integrase |
| 01/06/2005 | US20050004231 Method for inhibiting platelet aggregation |
| 01/06/2005 | US20050004230 Retroviral protease inhibitors |
| 01/06/2005 | US20050004229 Increasing survival of oligodendrocytes using deprenyl compound |
| 01/06/2005 | US20050004228 Long-acting drug combinations for the treatment of respiratory complaints |
| 01/06/2005 | US20050004227 Cell growth inhibitor |
| 01/06/2005 | US20050004226 Compositions and methods for amelioration of human female sexual dysfunction |
| 01/06/2005 | US20050004225 Oxidoreductase inhibitors and methods of screening and using thereof |
| 01/06/2005 | US20050004224 Reducing production of amyloid beta protein; fewer side effects |
| 01/06/2005 | US20050004222 Methods for prevention and treatment of gastrointestinal disorders |
| 01/06/2005 | US20050004221 Intrathecal gabapentin compositions |
| 01/06/2005 | US20050004220 Producing nontoxic solution through heat sterilization |
| 01/06/2005 | US20050004219 Implantable device having higher concentration of active material that is isotonic with cerebrospinal fluid; longer intervals between replacements |
| 01/06/2005 | US20050004218 Vaccenic acid |
| 01/06/2005 | US20050004217 Utilizing cistaceous plant extract; safe, side effect free; |
| 01/06/2005 | US20050004216 Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties |
| 01/06/2005 | US20050004211 Inhibiting topoisomerase I; blocking S or G2/M phase of tumor and/or cancer cells |
| 01/06/2005 | US20050004207 Substituted isoindoles and the use thereof |
| 01/06/2005 | US20050004206 suspending crystal strutured or amorphous lipitor in diluents comprising alcohols and/or water mixtures to cause conversion, then separating the diluents; monodispersity |
| 01/06/2005 | US20050004205 Such as 1-[N alpha -(1'-Acetoxyethoxycarbonyl)-N omega -(pyrazinyl-2-carbonyl)-L-ornithinyl]-pyrrolidine-2-carbonitrile; impaired glucose tolerance, type II diabetes, hypoglycaemia |
| 01/06/2005 | US20050004204 2-Iminopyrrolidine derivatives |
| 01/06/2005 | US20050004203 NAALADase inhibitors; effecting transforming growth factor beta or neuronal activity |